← Back to results
Federal

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Source: Congress.gov  ·  1,742 words in original text
This bill changes how Medicare covers certain medical devices called breakthrough devices. It creates a four-year period during which Medicare must cover these newly approved devices while the government reviews whether they should be permanently covered. ##
- Medicare patients (people entitled to benefits under part A or enrolled under part B) - Medical device manufacturers who apply for breakthrough device status - The Centers for Medicare & Medicaid Services (the agency that runs Medicare) ##
- Medicare must cover breakthrough devices during a four-year transitional coverage period starting when a device receives breakthrough designation, unless the device is not used according to FDA (Food and Drug Administration) labeling or poses an undue risk of harm that outweighs potential benefits (Sec. 2(a)(1)) - A device qualifies as a breakthrough device if it receives priority review from the FDA and meets other specified criteria, as determined by the Secretary of Health and Human Services (Sec. 2(a)(3)) - The Secretary must decide whether to grant breakthrough device designation within six months of a manufacturer's application (Sec. 2(a)(3)) - If the Secretary denies breakthrough device designation, the manufacturer must receive a written explanation identifying which specific criteria the device failed to meet (Sec. 2(a)(3)) - The Secretary must issue a final coverage decision for breakthrough devices before the four-year transitional period ends, if the coverage request was submitted at least nine months before the period ends (Sec. 2(b)) ##
Medicare coverage rules change to allow automatic coverage of certain newly approved medical devices for four years while the government completes its review process. Previously, devices might not have been covered during this waiting period. ##
- **Breakthrough device**: A medical device designated by the Secretary that meets specific FDA review and approval criteria (Sec. 2(a)(2)) - **Transitional coverage period**: The four-year period that begins when a device receives breakthrough device designation (Sec. 2(a)(2)) - **Clinical diagnostic laboratory test**: Not specified in bill text, but excluded from breakthrough device status ##
The process for designating breakthrough devices begins 18 months after this bill becomes law. Not specified in bill text when other provisions take effect.
Important: This plain English summary was generated by AI and is provided for informational purposes only. It is not legal advice. Always consult the official bill text on Congress.gov or a qualified attorney for legal matters.